» Articles » PMID: 36271204

Oral Delivery of Nucleic Acid Therapies for Local and Systemic Action

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2022 Oct 22
PMID 36271204
Authors
Affiliations
Soon will be listed here.
Abstract

Nucleic acid (NA) therapy has gained importance over the past decade due to its high degree of selectivity and minimal toxic effects over conventional drugs. Currently, intravenous (IV) or intramuscular (IM) formulations constitute majority of the marketed formulations containing nucleic acids. However, oral administration is traditionally preferred due to ease of administration as well as higher patient compliance. To leverage the benefits of oral delivery for NA therapy, the NA of interest must be delivered to the target site avoiding all degrading and inhibiting factors during its transition through the gastrointestinal tract. The oral route presents myriad of challenges to NA delivery, making formulation development challenging. Researchers in the last few decades have formulated various delivery systems to overcome such challenges and several reviews summarize and discuss these strategies in detail. However, there is a need to differentiate between the approaches based on target so that in future, delivery strategies can be developed according to the goal of the study and for efficient delivery to the desired site. The goal of this review is to summarize the mechanisms for target specific delivery, list and discuss the formulation strategies used for oral delivery of NA therapies and delineate the similarities and differences between local and systemic targeting oral delivery systems and current challenges.

Citing Articles

Deciphering the roles of non-coding RNAs in liposarcoma development: Challenges and opportunities for translational therapeutic advances.

Chong Z, Ho W, Yeap S Noncoding RNA Res. 2024; 11:73-90.

PMID: 39736850 PMC: 11683247. DOI: 10.1016/j.ncrna.2024.11.005.


Nucleic acid drugs: recent progress and future perspectives.

Sun X, Setrerrahmane S, Li C, Hu J, Xu H Signal Transduct Target Ther. 2024; 9(1):316.

PMID: 39609384 PMC: 11604671. DOI: 10.1038/s41392-024-02035-4.


mRNA vaccines: a new era in vaccine development.

Chandra S, Wilson J, Good D, Wei M Oncol Res. 2024; 32(10):1543-1564.

PMID: 39308511 PMC: 11413818. DOI: 10.32604/or.2024.043987.


Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress.

Dume B, Licarete E, Banciu M Mol Ther Nucleic Acids. 2024; 35(3):102256.

PMID: 39045515 PMC: 11264197. DOI: 10.1016/j.omtn.2024.102256.


Delivery of biologics: Topical administration.

Kulchar R, Singh R, Ding S, Alexander E, Leong K, Daniell H Biomaterials. 2023; 302:122312.

PMID: 37690380 PMC: 10840840. DOI: 10.1016/j.biomaterials.2023.122312.


References
1.
Vargason A, Anselmo A, Mitragotri S . The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021; 5(9):951-967. DOI: 10.1038/s41551-021-00698-w. View

2.
Kulkarni J, Witzigmann D, Thomson S, Chen S, Leavitt B, Cullis P . The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021; 16(6):630-643. DOI: 10.1038/s41565-021-00898-0. View

3.
Mali P, Yang L, Esvelt K, Aach J, Guell M, DiCarlo J . RNA-guided human genome engineering via Cas9. Science. 2013; 339(6121):823-6. PMC: 3712628. DOI: 10.1126/science.1232033. View

4.
de Smet M, Meenken C, van den Horn G . Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm. 1999; 7(3-4):189-98. DOI: 10.1076/ocii.7.3.189.4007. View

5.
Kaczmarek J, Kowalski P, Anderson D . Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017; 9(1):60. PMC: 5485616. DOI: 10.1186/s13073-017-0450-0. View